Early Access — free while we kick the tires
EdgarHawk

SULLIVAN LOUIS W

Director

Director
2 filings analyzed · 1 company · Latest 2025-12-23

Companies

Company Buys Sells Direction
UNITED THERAPEUTICS Corp UTHR 0 30 Net selling

Activity

December 2025
high
Sell
5,950 shares
$3,047,201
Significance 8/10

Director Sullivan exits UTHR entirely, selling 5,950 shares for $3,047,200.66 on 2025-12-22

Director Louis W Sullivan completed a total exit of his UTHR position, liquidating all 5,950 shares across two separate sales for a combined $3,047,200.66 at an average price of $512.13, reducing his holdings from 6.0K shares to zero. His cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 100.00%, and notably, all 5 of his prior UTHR sales in December 2024 exhibited strong timing, with the stock declining 2.0% to 6.1% within 30 days of each sale. The stock has since appreciated 7.5% over the past 30 days and 16.3% over the past 90 days from the recent transaction date, moving near its 52-week high of $517.13. This represents a significant departure from Sullivan's established pattern of well-timed exits, as the stock has risen rather than fallen post-sale, breaking his historical track record of sales preceding declines.

December 2024
high
Sell
26,209 shares
$9,781,715
Significance 7/10

Director Louis W. Sullivan sold 26,209 shares for $9,781,714.73 in 23 transactions on 2024-12-18, reducing holdings 89.1% to 3,200 shares.

Director Sullivan executed a substantial multi-tranche liquidation of his UTHR position on a single day, selling 26,209 shares (26.2K shares) across 23 separate transactions for an aggregate $9,781,714.73 ($9.8M), with a blended average price of $373.22 and prices ranging from $366.11 to $382.63. The sale reduced his holdings by 89.1%, leaving only 3,200 shares (3.2K shares) post-transaction. This dramatic reduction in equity stake contrasts with recent market performance: the stock is currently at $360.16, 12.2% below its 52-week high of $410.00, and near the upper end of its annual trading range. His prior two sales at UTHR in May 2024 were not well-timed at the 90-day mark, as the stock subsequently rose 26.5% to 27.4% after those sales; this December transaction occurred after a 2.0% 90-day gain and a flat 30-day performance. Given the company's strong fundamentals (annual revenue growth of +20.2%, P/E of 14.48, $309.1M net income on $748.9M quarterly revenue), the motivation for this near-complete exit warrant observation, particularly given the sustained post-transaction holdings level at only 3.2K shares and the price proximity to historical highs.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access